Compositions for improving joint health

Abstract

The present disclosure is related to dietary supplements. For example, this disclosure relates to compositions that include, for example, one or more agents that decrease the concentration of cyclooxygenase-2, decrease the concentration of transient receptor potential cation channel subfamily V member 1, and/or decrease calcitonin gene-related peptide concentration. In some embodiments, a composition as provided herein includes apigenin present in an amount of about 1% to about 5% w/w of the composition; and hesperidin present in an amount of about 90% to about 99% w/w of the composition. Such compositions are useful for decreasing joint pain and/or inflammation.

1 . A method for decreasing joint inflammation in a subject in need thereof comprising administering to the subject a composition comprising two or more agents that decrease the concentration of cyclooxygenase-2 (COX-2). 
     
     
         2 . The method of  claim 1 , wherein the joint inflammation is associated with one or more of: an injury, ankylosing spondylitis, bursitis, gout, juvenile rheumatoid arthritis, lupus, Lyme disease, osteoarthritis, pseudogout, psoriatic arthritis, rheumatoid arthritis, and tendonitis. 
     
     
         3 . (canceled) 
     
     
         4 . The method of  claim 1 , wherein at least one agent that decreases the concentration of COX-2 also decreases one or more of: prostaglandin E 2  (PGE 2 ) concentration; the concentration of reactive oxygen species (ROS); and COX-2 expression. 
     
     
         5 . (canceled) 
     
     
         6 . The method of  claim 1 , wherein at least one agent that decreases the concentration of COX-2 modulates COX-2 synthesis. 
     
     
         7 . (canceled) 
     
     
         8 . The method of  claim 4 , wherein at least one agent that decreases the concentration of PGE2 modulates arachidonic acid metabolism. 
     
     
         9 . The method of  claim 4 , wherein the at least one agent that decreases the concentration of ROS modulates an oxidative stress pathway. 
     
     
         10 . The method of  claim 1 , wherein the two or more agents that decrease COX-2 concentration comprise:
 a flavone: and   a flavanone.   
     
     
         11 . A method for decreasing joint pain of a subject comprising administering to the subject a composition comprising two or more agents that decrease the concentration of transient receptor potential cation channel subfamily V member 1 (TRPV1 ); decreases the concentration of calcitonin gene-related peptide (CGRP); or a combination thereof. 
     
     
         12 . The method of  claim 11 , wherein the joint pain is associated with one or more of: an injury, adult Still’s disease, ankylosing spondylitis, avascular necrosis, bone cancer, bursitis, complex regional pain syndrome, fibromyalgia, gonococcal arthritis, gout, hypothyroidism, juvenile idiopathic arthritis, leukemia, lupus, Lyme disease, osteoarthritis, osteomyelitis, Paget’s disease of bone, polymyalgia rheumatic, pseudogout, psoriatic arthritis, reactive arthritis, rheumatic fever, rheumatoid arthritis, rickets, sarcoidosis, septic arthritis, and tendinitis. 
     
     
         13 . (canceled) 
     
     
         14 . The method of  claim 11 , wherein at least one agent also modulates PGE 2  signaling. 
     
     
         15 . The method of  claim 11 , wherein the two or more agents that decrease the concentration of TRPVI; decrease the concentration of CGRP; or a combination thereof, comprise:
 a flavone: and   a flavanone.   
     
     
         16 . The method of  claim 15 , wherein the flavanone is a trihydroxyflavanone. 
     
     
         17 . The method of  claim 16 , wherein the trihydroxyflavanone is selected from the group consisting of: hesperidin, butin, garbanzol, naringenin, pinobanksin, and a combination thereof. 
     
     
         18 . The method of  claim 17 , wherein the flavanone is hesperidin. 
     
     
         19 . The method of  claim 15 , wherein the flavanone is present in an amount of about 30% to about 99% w/w of the composition. 
     
     
         20 - 22 . (canceled) 
     
     
         23 . The method of  claim 15 , wherein the flavone is a trihydroxyflavone. 
     
     
         24 . The method of  claim 23 , wherein the trihydroxyflavone is selected from the group consisting of: apigenin, baicalein, norwogonin, galangin, and a combination thereof. 
     
     
         25 . The method of  claim 24 , wherein the flavone is apigenin. 
     
     
         26 . The method of  claim 15 , wherein the flavone is present in an amount of about 0.01 % to about 50% w/w of the composition. 
     
     
         27 - 30 . (canceled) 
     
     
         31 . The method of any one of  claim 15 , wherein the flavanone is hesperidin and the flavone is apigenin. 
     
     
         32 - 36 . (canceled)